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ABSTRACT Biochemical experiments have recently revealed that the p-S8 peptide, with an amino-acid sequence identical to
the conserved fragment 83–93 (S8) of the HIV-1 protease, can inhibit catalytic activity of the enzyme by interfering with protease
folding and dimerization. In this study, we introduce a hierarchical modeling approach for understanding the molecular basis of
the HIV-1 protease folding inhibition. Coarse-grained molecular docking simulations of the ﬂexible p-S8 peptide with the ensem-
bles of HIV-1 protease monomers have revealed structurally different complexes of the p-S8 peptide, which can be formed by
targeting the conserved segment 24–34 (S2) of the folding nucleus (folding inhibition) and by interacting with the antiparallel
termini b-sheet region (dimerization inhibition). All-atom molecular dynamics simulations of the inhibitor complexes with the
HIV-1 PR monomer have been independently carried out for the predicted folding and dimerization binding modes of the p-S8
peptide, conﬁrming the thermodynamic stability of these complexes. Binding free-energy calculations of the p-S8 peptide and its
active analogs are then performed using molecular dynamics trajectories of the peptide complexes with the HIV-1 PR monomers.
The results of this study have provided a plausible molecular model for the inhibitor intervention with the HIV-1 PR folding and
dimerization and have accurately reproduced the experimental inhibition proﬁles of the active folding inhibitors.
INTRODUCTION
Human immunodeficiency virus type 1 protease (HIV-1 PR)
is a homodimeric enzyme which plays an important role in
processing the viral polypeptide precursors (1–3). Crystal
structures of the HIV-1 PR complexes have revealed that the
protease flaps can exhibit a considerable mobility ranging
from a closed form (in which the active site is occupied by a
ligand), semiopen form (which is typically observed in the
free HIV-1 PR), and a wide-open form (which allows the
substrate and inhibitor access to the active site) (4–8). NMR
experiments have shown that localized fluctuations of the
HIV-1 PR flaps reflect a rapid dynamic equilibrium between
the ensembles of semiopen and closed conformations, which
are observed in the crystal structures of the HIV-1 PR. The
ensemble of HIV-1 PR unbound structures can also include
open-flap conformations as a rare event in a slow conforma-
tional exchange (9–12). Understanding HIV-1 PR flexibility
and dynamics associated with the binding of HIV-1 PR sub-
strates and inhibitors has been greatly enhanced using synergy
of experiments and simulations. Mechanisms of HIV-1 PR
flexibility and dynamics were studied at the atomic level,
including flap openings in the activated dynamics studies
(13,14), curling motions of the flaps observed in the long
molecular dynamics (MD) simulations (15,16), high flexibil-
ity and opening of the flaps in the simulations of theHIV-1 PR
andmutants (17–21), and role of solvation effects influencing
flap collapse (22). The reduced complexity of a coarse-
grained model of the HIV-1 PR dynamics has enabled us to
capture statistically significant conformational transitions
between open and closed forms of the protease and an accu-
rate thermodynamic analysis of the HIV-1 PR motions oc-
curring on the microsecond timescale (23–26). Recently,
large-scale unconstrained all-atom MD simulations of HIV-1
PR have demonstrated the reversible opening of the flaps and
evidence for multiple transitions between the closed, semi-
open, and open conformations, in which rare opening events,
when flaps separate and become less ordered, are accompa-
nied by subsequent return to the thermodynamically stable
semiopen state (27,28). The ability of certain mutants to alter
the dynamic equilibriumbetween the open and closed enzyme
forms of the HIV-1 PR may lead to an excessive stabilization
of the semiopen conformation and drug-resistant forms of the
enzyme (29–35).
The major areas that constitute the dimer interface are
the active site region 24–29, forming the fireman’s-grip hy-
drogen-bond network, and the four-stranded anti-parallel
b-sheet, which is formed by interdigitation of the C-terminal
and N-terminal residues of the HIV-1 PR. These interfaces
are assembled from evolutionary and structurally conserved
fragments 24–34 (S2) and 83–93 (S8) of the HIV-1 PR
monomers, which constitute the critical components of the
HIV-1 PR folding nucleus (Fig. 1 A). The protection patterns
obtained for the HIV-1 PR units 24–34, 74–78, and 83–93
have shown that these conserved segments constitute the
protease folding core (36). Although many crystal structures
of HIV-PR and its complexes with various ligands have been
solved, crystals of the natural HIV-PR monomer are difficult
to obtain, due to the low dissociation constant of dimer and
equilibrium concentration of monomer in solution. Solution
NMR structures of the HIV-1 PR monomers have revealed
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similar tertiary folds of the HIV-1 PR monomer and a single
subunit of the HIV-1 PR dimer, with some disorder in the
terminal regions (37–40). Furthermore, destabilization of the
interfacial network in the R87K, D29N, and T26A mutants
can result in the formation of a stable monomeric structure
of the HIV-1 PR single subunit. A comprehensive view of
protein dynamics was recently inferred from NMR studies of
the HIV-1 PR, suggesting that the flaps in the unliganded
protease dimer may interact with each other in solution and
that semiopen form may be a dominant conformation of the
unliganded HIV-1 PR dimer and monomer (12,41). Ac-
cording to the computer simulations of the HIV-1 PR folding,
the HIV-1 PR active dimer is likely formed by the association
of folded HIV-1 PR monomers rather than by direct coupling
between the monomer folding and binding (42). The dy-
namics of the HIV-PR monomer has been further explored
using MD simulations of the HIV-PR monomer in water,
which have revealed that stabilization of the termini in the
b-sheet may be a dominant conformation of the solvated
HIV-PR monomer (43).
The diversity of the HIV-1 PR inhibition scenarios may
include the conventional active site binding and alternative
inhibitory mechanisms, based on blocking the assembly of
the HIV-1 PR homodimer and disrupting the dimeric inter-
face. Design of HIV- PR dimerization inhibitors is typically
focused on disrupting four-stranded b-sheet and targeting
flexible N- and C-termini that constitute most of the dimer
interface (44–47). It was recently proposed that the peptide
LDTGADDTVLE (p-S2) and the peptide NIIGRNLLTQI
(p-S8), with the sequences identical to that of the conserved
fragments 24–34 (S2) and 83–93 (S8) from the protease
folding nucleus, may act as unconventional therapeutic agents
intervening with the HIV-1 PR folding and dimerization
(48–52). In particular, it was demonstrated that the p-S8
peptide (Fig. 1 A) can inhibit the enzyme folding and for-
mation of the active dimer in the micromolar range (Ki¼ 2.58
mM) (48,49). The biochemical and circular dichroism spec-
troscopy experiments have further confirmed that the p-S8
peptide can inhibit catalytic activity of the enzyme, interfere
with the assembly of the HIV-1 PR folding nucleus, and lead
to partial destabilization of the active HIV-1 PR dimer
(48–52). To improve pharmacological profiles of the folding
inhibitor, a number of the p-S8 peptide analogs have been
synthesized, including a shortened 83–92 derivative
NIIGRNLLTQ and a N88D mutant NIIGRDLLTQI (Fig.
1 B). Both peptide analogs have exhibited a considerably
better solubility than the wild-type folding inhibitor with the
inhibition constants of Ki ¼ 7.8 mM for a shortened 83–92
peptide and Ki¼ 15.8 mM for the N88D peptide mutant (48–
52). Simulations of the p-S2 and p-S8 peptides in explicit
solvent have provided the details of the docking mechanism
of the two peptides (52). This study has shown that the p-S8
peptide can spontaneously fold into the structure of the 83–93
protease segment independently of the rest of the protein and
retain the thermodynamic stability of this structure in isola-
tion. In contrast, the peptide p-S2, corresponding to the
fragment 24–34 of the protease-folding nucleus, is consid-
erably more flexible. According to this study, binding of the
p-S2 and p-S8 peptides may result in a stable complex,
whereby a flexible p-S2 peptide can wrap around a folded
structure of the p-S8 peptide by forming a network of specific
hydrogen bonds, none of which involve residues from a
single a-helix region (52).
The ultimate experiments probing the folding inhibition
mechanism require a combination of biochemical and struc-
tural studies. However, x-ray crystallography is not readily
applicable for these studies, since the necessary high con-
centrations of the enzyme would tend to shift the equilibrium
toward the active dimer. NMR studies of the inhibitor inter-
vention with the HIV-1PR dimer assembly are quite chal-
lenging, thoughmay in principle assess the molecular basis of
folding inhibition. We propose a hierarchical modeling
strategy to dissect the molecular and energetic basis of the
HIV-1 PR folding inhibition at atomic resolution. This ap-
proach includes the following stages:
1. Coarse-grained molecular docking simulations of the
flexible p-S8 peptide with the ensembles of HIV-1 PR
dimers and monomers (explicit flexibility of the inhibitor
and implicit flexibility of the receptor) and subsequent
free energy refinement of the low-energy docking solu-
tions.
FIGURE 1 (A) Evolutionary and structurally conserved segments of the
HIV-1 PR core are highlighted: the b-strand segment 24–34 and the 83–93
segment encompassing a single a-helix. (B) The folded units 83–93 and 24–
34 of the HIV-1 PR core are shown in grayscale ribbons.
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2. All-atom MD simulations of the flexible peptide—HIV-1
PR monomer complexes performed for the predicted fold-
ing and dimerization binding modes of the p-S8 peptide
(explicit flexibility of both the inhibitor and the receptor).
3. Binding free energy calculations of the p-S8 peptide and its
active analogs, which are performed using all-atom MD
trajectories of the peptide complexes with the HIV-1 PR
monomers in the folding and dimerization binding modes.
Using this hierarchical simulation approach, we demon-
strate that the folding inhibitor may exhibit both folding and
dimerization modes of inhibition by targeting conservative
elements of the HIV-1 PR folding core and dimerization in-
terface. This computational analysis presents a plausible
molecular mechanism of the inhibitor intervention with the
HIV-1 PR folding and dimerization, which is consistent with
the available experimental data.
MATERIALS AND METHODS
HIV-1 PR conformational ensembles
The conformational ensemble of the HIV-1 PR crystal structures provides a
convenient coarse-grained model of the enzyme mobility, reflecting a spec-
trum of the flap opening motions which are difficult to detect in the MD
simulations. According to the recent structural analysis and classification of
the HIV-1 PR apo structures (53,54), distinct families in HIV-1 PR may in-
clude semiopen, curled, and open conformations. The ensemble of presently
available crystal structures of the apo HIV-1 PR was used in docking simu-
lations to categorize structural landscape of the HIV-1 PR conformational
states. This includes semiopen conformations with pdb entries 1hhp (55) and
3hvp (56). The curled-flaps conformations include pdb entries 3phvwild-type
(57), 2g69 P53L mutant (58), 2hb4 2.15 A˚ wild-type, and 2hb2 2.3 A˚ sixfold
L24I/M46I/F53L/L63P/V77I/V82A mutant) (53,54). The open-flaps con-
formations include pdb entries 2pc0 1.4 A˚ resolution wild-type (54), 1rpi
ninefold mutant (59), and 1tw7 10-fold mutant (8). The HIV-1 PR confor-
mations in complexes with the clinically approved HIV-1 inhibitors saqui-
navir, ritonavir, indinavir, nelfinavir, and amprenavir were used to represent a
closed form of the enzyme (60–64). Overall, the ensemble of the HIV PR
crystal structures can thereby represent a coarse-grained model of the flap-
opening mechanism. The conformational ensemble of the HIV-1 monomeric
conformations is initially obtained from the crystal structures of the un-
ligandedHIV-1 PR andHIV-1 PR complexeswith the inhibitors, followed by
subsequent minimization and thermal equilibration procedures. The proton-
ation state ofAsp25of every structurewas adjusted as protonated according to
experimental observations predicting that, under physiological conditions,
only one of the two active site aspartates is protonated while the other remains
in the carboxylated form. We have equilibrated the HIV-1 PR dimeric and
monomeric structures at 300 K using MD simulations performed with the
GROMACS package and OPLS/AMBER force field with 9428 water mol-
ecules and two chloride ions (65–67). The following steps were carried out:
1), a steepest descent energy minimization; 2), equilibration of water for 300
ps at 300 K keeping the heavy atoms of the protein constrained; and 3), a 300
ps dynamics at 300 K at constant volume to thermalize the system.
Coarse-grained molecular docking with the
ensembles of the HIV-1 PR conformations
The knowledge-based simplified energetic model used in docking simulations
includes intramolecular energy terms for the ligand, given by torsional and
nonbonded functions, and intermolecular ligand-protein steric and hydrogen-
bond interaction terms calculated from a piecewise linear potential summed
over all protein and ligand heavy atoms (68). The piecewise linear potential
parameters were refined to yield the experimental crystallographic structure of
a set of ligand-protein complexes as the global energy minimum. Multiple
docking simulations are performed using an evolutionary search algorithm
based on the ideas of natural selection (68). For each docking simulation,
the evolutionary search was performed for a total of 120 generations with a
population size of 1200 members. During the course of 500 independent
docking simulations peptide conformations and orientations are sampled in a
parallelepiped that encompasses the binding site obtained from the crystallo-
graphic structure of the HIV-1 PR complexes with a large 20.0 A˚ cushion
added to every side of this box surrounding the interface. The protein structure
is held fixed in its minimized and equilibrated conformation, while rigid-body
degrees of freedom and the peptide rotatable angles are treated as independent
variables. Each member of the evolving population represents an encoded
vector consisting of the rigid-body coordinates and the torsional angles about
the peptide rotatable bonds. The initial peptide conformations are generated by
randomizing the encoded vector, where the center of mass of the ligand is
restricted to the rectangular parallelepiped that encompasses the HIV-1 PR
crystal structures. The three rigid-body rotational degrees of freedom, as well
as the torsional angles for all rotatable bonds are uniformly initialized between
0 and 360. Bonds allowed to rotate include those linking sp3 hybridized atoms
to either sp3 or sp2 hybridized atoms and single bonds linking two sp2 hy-
bridized atoms. The employed coarse-grained modeling allows
1. An unbiased sampling of the large conformational space which entirely
encompasses the ensemble of the HIV-1 PR conformations.
2. Effectively characterize the multitude of the binding modes for the folded
inhibitor and determine putative binding interfaces of the inhibitors.
Molecular dynamics simulations
We have carried out two separate 10-ns simulations using the predicted
folding and dimerization peptide binding modes with the HIV-1 PR mono-
mers. MD simulations were done using NAMD 2.6 with the CHARMM22
force field (69). The respective systems were solvated in cubic boxes of
TIP3P water, which extended at least 15 A˚ away from any given protein
atom. The systems were then neutralized by adding the counterions Na1 and
Cl using Autoionize plug-in of VMD. The equilibration stage of simula-
tions included:
1. Energy minimization of the protein for 5000 steps of steepest descent
minimization converging to a value of 2000 kJ mol1 nm1.
2. Solvation and energy minimization of the system for 10,000 steps.
3. The entire system was subjected to a gradual temperature increase from
30 K to 300 K in intervals over 15 ps by increasing the temperature of
Langevin damping and Langevin piston by 20 K in each step.
An NPT ensemble was used with periodic boundary conditions. Pressure
was maintained at 1 atm using the Langevin piston method with a damping
coefficient of 10 ps1. The entire system was then equilibrated for 500 ps.
Electrostatic interactions were computed using the particle-mesh Ewald al-
gorithm (70). The list of nonbonded interactions was truncated at 10 A˚ and a
switching cutoff distance of 8 A˚ is used for theLennard-Jones interactions.All
bonds involving hydrogen atoms were constrained using the SHAKE algo-
rithm. A time-step of 2 fs was employed. During the productive phase,
pressure and temperature were maintained at 1 atmosphere and 300 K re-
spectively by using the Langevin pistonmethodwith a damping coefficient of
1 ps1.
Binding free energy calculations
Binding free energies computations are done using the molecular mechanics
AMBER force field (71) and the solvation energy term based on continuum
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generalized-Born and solvent-accessible surface area (GB/SA) solvation
model (72,73). The details of the MM/GBSA model used in free energy
simulations of biological systems have been extensively documented in our
earlier studies (74–78). Here, for completeness of the presentation, we briefly
outline the major ingredients of the computational model used in this study.
The binding free energy of the ligand-protein complex is computed as
Gbind ¼ Gcomplex  Gprotein  Gligand; (1)
Gmolecule ¼ Gsolvation1EMM  TSsolute; (2)
whereGsolvation is the solvation free energy,EMM is themolecular mechanical
energy of the molecule summing up the electrostatic Ees interactions, van der
Waals contributions Evdw, and the internal strain energy Eint
EMM ¼ Ees1Evdw1Eint; (3)
Solvation free energy Gsolvation can be divided into nonpolar Gnonpol and
polar Gpol components,
Gsolvation ¼ Gnonpol1Gpol: (4)
The nonpolar contributionGnonpol to the solvation free energy is computed as
a function of the solvent accessible surface area (SA),
Gnonpolar ¼ Gcavity1Gvdw ¼ +
i
siSAi: (5)
In the GB/SA model, the Gcavity and Gvdw contributions are combined
together via evaluating solvent-accessible surface areas.
The polar contribution Gpol to the solvation energy is computed as fol-
lows:
Gpol ¼ 166:0 1 1
e
 
+
i
+
j
qiqj
ðr2ij1a2ijexpðDijÞÞ0:5
: (6)
The quasiharmonic approximation is typically used in the MM/GBSA
calculations to assess the order of magnitude for the entropy loss during
binding. Ssolute is the vibrational entropy of the molecule. The normal mode
analysis is carried out and vibrational entropy is computed from classical
statistical mechanics formula with the AMBER module nmode for the
energy-minimized structures of the complex, the free protein, and free
peptide without water molecules. A dielectric constant of 4rij, where rij is the
distance between atoms i and j of the molecule, is used in the normal mode
calculations.
Binding free energy evaluations can be performed using either separate
trajectories of the complex, protein, and ligand (separate-trajectory protocol)
or from a trajectory of the complex (single-trajectory protocol) (79). A single-
trajectory protocol utilizes only the MD simulation of the complex, followed
by separating a single trajectory of the complex into snapshots of the complex,
the free protein, and the free ligand. In contrast, a separate-trajectory method
involves analysis of three different independentMD simulations and uses the
respective snapshots of the complex, the free protein, and the free ligand to
compute the free energy of binding. These calculations are physically more
meaningful and should, in principle, produce more accurate binding free
energies, but at the potential expense of somewhat larger error bars. We have
used both a single-trajectory protocol and a separate-trajectory method to
compare the quality and consistency of the predictions using these ap-
proaches. Binding free energy evaluations are performed using MD trajec-
tories of the p-S8 peptide complexes with the HIV-1 PR monomers in the
folding and dimerization binding modes. In a single-trajectory protocol, the
structures for the uncomplexed protease monomer and the peptide are gen-
erated by using the corresponding samples of the complex and separating the
protein and peptide coordinates, followed by an additional minimization of
the unbound protease monomer and unbound inhibitor. A single-trajectory
protocol is less computationally intensive and may also be less sensitive be-
cause of cancellation of the intramolecular energies, caused by neglecting the
effects of structural adaptation during binding. In a separate-trajectory pro-
tocol, we have performed three independent MD simulations of the complex,
the peptide inhibitor, and the HIV-1 PR monomer. The obtained samples of
the complex, the inhibitor, and the protease monomer have been used to
compute the binding free energies.We assume that the predicted structures of
the p-S8 peptide in complexes with the HIV-1 PR monomers are robust
against minor chemical modifications of the truncated 83–92 analog
NIIGRNLLTQ and the N88D mutant NIIGRDLLTQI. We have verified that
this assumptionmay be indeed valid for our systems, because the equilibrium
sampling of the active peptide analogs on a timescale of up to 2 ns follows
closely the trajectory of the p-S8 folding inhibitor (data not shown). Conse-
quently, the MM/GBSA binding free energy calculations of the peptide an-
alogs have been performed combining the results of two independent long
10-ns MD trajectories of the wild-type p-S8 peptide in the folding and di-
merization modes of inhibition. A respective mutation to the p-S8 peptide is
introduced into each of the system snapshots and followed with the 10,000
steps of energy minimization.
RESULTS AND DISCUSSION
Coarse-grained peptide docking with the
ensemble of the HIV-1 PR monomers
Molecular docking simulations of the p-S8 inhibitor have
been conducted using a simplified, knowledge-based energy
model with the ensembles of the HIV-1 PR dimers and
monomers. Simulations were first carried out with the inter-
nally rigid peptide, kept in its native folded conformation and
then with the fully flexible peptide, given the initial randomly
distributed and fully extended inhibitor conformations. In this
coarse-grained docking method, the explicit flexibility of the
inhibitor is simulated given the implicit flexibility of the re-
ceptor, which is provided by structural differences within the
ensemble of the HIV-1 PR conformations. This approach
expands the realm of structural receptormodels in simulations
and assumes the presence of an ensemble of the multiple
conformational states for both interacting molecules, which is
similar to a conformational-selection model of biomolecular
binding (80–83). Although theremay exist certain differences
in the timescale of the flap motions in the HIV-1 PR mono-
meric and dimeric states, the tertiary folds of the HIV-1 PR
monomer, and a single subunit of the HIV-1 PR dimer are
very similar, and can therefore exhibit a similar dynamic ex-
change between closed, open, and semiopen forms of the
enzyme. On the other hand, global conformational fluctua-
tions of the enzyme, such as those revealed by x-ray crystal-
lographic studies, are difficult to directly probe in the flexible
docking simulations. The proposed coarse-grained molecular
docking of the flexible p-S8 peptide with the ensembles of
HIV-1 PR structures and subsequent binding free energy re-
finement of the low-energy docking solutions presents a ro-
bust, yet an opportunistic approach for predicting binding
modes of the inhibitor.
Structural analysis has revealed that the folded p-S8 pep-
tide cannot be accommodated in the active site of the HIV-1
PR dimer, even with the flaps in their semiopen (pdb entry
1HHP) and wide-open (pdb entry 1tw7) forms. In contrast,
we have discovered that low-energy complexes of the folded
peptide can be preferably formed with the HIV-1 PR mono-
mers, which may facilitate the inhibitor intervention with the
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HIV-1 PR folding and dimerization. Based on these
preliminary insights and hypothesis, we have proceeded by
simulating the p-S8 peptide folding and binding with the
HIV-1 PR monomers. A series of 500 independent fully
flexible docking simulations of the p-S8 peptide (with a total
of 55 flexible bonds treated as independent degrees of free-
dom) have been performed with the ensemble of HIV-1 PR
monomeric states. The binding free energy refinement of the
coarse-grained docking solutions has identified two domi-
nant classes of low-energy peptide conformations with the
binding energetics in the range of 6 kcal/mol to 8 kcal/
mol (Fig. 2). These structurally different, low-energy binding
modes of the inhibitor are formed by either targeting the
conserved segment 24–34 of the enzyme folding nucleus
(folding inhibition mechanism) (Fig. 3, A and B) or interacting
with the antiparallel b-sheet of the termini (dimerization in-
hibition mechanism) (Fig. 3, C and D). The low-energy pep-
tide conformations correspond to a folded, a-helix-based
structure of the 83–93 protease fragment and suggest a pos-
sibility of folding and binding coupling (80–83), according to
which folding of the peptide may be required to ensure
structural mimicry with the key elements of the HIV-1 PR
dimer interface. The root mean-square deviations (RMSD) of
the docked conformations are reported in the reference to the
lowest energy structure of the p-S8 inhibitor corresponding
to the folding mode of inhibition and reflect two struc-
tural clusters of low-energy docking solutions (Fig. 2 B). The
docking results suggest that there may exist two dominant
binding modes of the inhibitor: the first one corresponds
to the folding mode of inhibition (conformations residing
within RMSD ¼ 2.0–2.5 A˚ from the reference conformation
and binding energies in the range of6 kcal/mol to 8 kcal/
mol) and the second dimerization mode of binding (confor-
mations residing within much larger RMSD¼ 6.0 A˚ from the
reference conformation and similar energetics in the range of
6 kcal/mol to 8 kcal/mol).
In the first low-energy binding mode (referred to in the text
as the folding binding mode), the folded p-S8 peptide is
packed perpendicular to the conserved 24–34 fragment of the
folding core (Fig. 3 A). The network of intermolecular hy-
drogen bonds which may be formed in the folding binding
mode (Fig. 3 B) includes:
FIGURE 2 (A) The MM/GBSA binding free energies as
a function of simulation run obtained from 500 flexible
docking simulations. (B) The RMSD values of the docked
conformations are reported in the reference to the lowest
energy structure of the p-S8 inhibitor corresponding to the
folding mode of inhibition and reflect two structural clusters
of low-energy docking solutions.
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1. Interactions between carbonyl oxygen of Ile-84 from the
peptide and backbone NH of Gly-27.
2. Interactions between the carboxylic acid group of the
Asn-83 side chain from the peptide and the side-chain
hydroxyl group of Thr-26.
3. Interactions between the side chains of the peptide Asp-
88 and catalytic Asp-25.
Moreover, hydrogen bonds may be formed between the
inhibitor and the backbone of the conserved Gly-49 and Ile-
50 residues, which are unlikely to be mutated in the active
protease variants (Fig. 3 B). The predicted hydrogen-bond
interactions, which may be formed by the folded peptide with
Asp-25, Thr-26, and Gly-27, mimic closely the fireman’s-
grip network of hydrogen bonds in the active HIV-1 PR di-
mer (Fig. 3, A and B). The predicted alternative mode of the
peptide binding (referred in the text as the dimerization
binding mode; see also Fig. 3, C and D) is prevalent in ra-
tionalizing dimerization inhibition mechanism and was re-
cently confirmed by NMR experiments for a class of peptidic
dimerization inhibitors (84). In this binding mode, the folded
p-S8 peptide can interact with the residues from the anti-
parallel b-sheet of the HIV-1 PR monomer and mimics a
(Fig. 3 C). The specific interactions formed by the peptide in
the dimerization binding mode include:
1. Hydrogen bonds formed by the side-chain amide group
of the peptide Asn-83 with the Thr-96 and Ile-3 monomer
residues.
2. Hydrogen-bonding formed between NH of Ile-85 and car-
bonyl oxygen of the protease Asn-98.
3. Interactions between the amide group of the Asn-88
carboxamide side chain and carbonyl oxygen of Leu-5
(Fig. 3 D).
The predicted binding modes of the p-S8 peptide with the
HIV-1 PR monomers specify the low-energy structures,
which may be formed by the folding inhibitor and provide a
rationale for both folding and dimerization modes of inhibi-
tion. According to the proposed structural models of binding,
the folding inhibitor may target the conserved HIV-1 PR re-
gions mimicking specific interactions in the active HIV-1 PR
dimer and thereby facilitate the inhibitor intervention with the
HIV-1 PR folding and dimerization. In particular, folding
mode of the p-S8 peptide inhibition may ensure structural
mimicry of the binding interface with the fireman’s-grip ar-
chitecture of the monomer-monomer protease interactions
(Fig. 4). The folding and binding coupling mechanism of the
peptide inhibition is also consistent with a plausible scenario
of the HIV-1 PRmonomer destabilization through interfering
with the formation of the HIV-1 PR folding core.
FIGURE 3 Structural characterization of the
peptide-binding modes in complexes with the
HIV-1 monomers. (A) The thermodynamically
stable conformation of the rigid p-S8 peptide (in
light blue) in the complexwith theHIV-1mono-
mer (orange ribbons). The predicted folded
conformation of the flexible p-S8 peptide (in
yellow) binds to the HIV-1 PR monomer (green
ribbons) in the same binding mode as deter-
mined in simulations with the rigid peptide. The
bound peptide conformations overlayed with
the conformationof the secondHIV-1PRmono-
mer (violet ribbons) reveals structural mimicry
with the fireman’s-grip hydrogen-bond network
present in the active dimer. (B) A closeup of
the binding interface and specific interactions
formed by the folded peptide in the folding
mode of inhibition. (C) An alternative binding
mode of the rigid p-S8 peptide (in light blue) and
folded conformation of the flexible p-S8 pep-
tide (in yellow) in the complex with the HIV-1
monomer (orange ribbons). The bound peptide
conformations overlayed with the conformation
of the second HIV-1 PR monomer (violet rib-
bons) mimics another important region of the
dimerization interface. (D) A closeup of the
binding interface and specific interactions
formed by the folded peptide in the dimerization
mode of inhibition. Atom-based representation
of the peptide is shown in default colors and
HIV-1 PR monomer conformations are shown
in green ribbons.
HIV-1 Protease Folding Inhibition 555
Biophysical Journal 95(2) 550–562
All-atom molecular dynamics simulations of the
peptide binding with the HIV-1 PR monomers
All-atom MD simulations of the inhibitor binding with the
HIV-1 PR monomer are then performed to verify thermo-
dynamic stability of the inhibitor complexes and suggest a
possible mechanism of inhibiting HIV-1 PR folding and di-
merization. In principle, a single long simulation of peptide
binding with the HIV-1 PR monomers should ultimately
result in conformational transitions between low-energy
binding modes and allow to accurately evaluate the relative
contribution of the folding and dimerization modes of inhi-
bition to the thermodynamic equilibrium. In practice, how-
ever, it is unrealistic to expect MD simulations to adequately
sample, structurally, very different binding interfaces of the
peptide with the ensemble of HIV-1 PR monomers. Conse-
quently, we have conducted separate 10 ns all-atom MD
simulations, initiated from the predicted low-energy com-
plexes corresponding respectively to the folding and dimer-
ization binding modes of the p-S8 peptide. In these
equilibrium MD simulations, which are subsequently used to
calculate binding affinities of the folding inhibitors, flexi-
bility of both the inhibitor and the receptor are explicitly
considered. The atomic details of the peptide inhibition
mechanism are determined by the equilibrium distribution of
the inhibitor and protease monomer conformational states in
the thermodynamically stable complexes.
Examination of the MD trajectories shows that after an
;1-ns period of relaxation, the folding binding mode of the
peptide complexwith theHIV-1 PRmonomer results in stable
backbone fluctuations of RMSD ¼ ;1–1.5 A˚ for both the
monomer and the peptide during the simulations (Fig. 5 A).
The respective thermal fluctuations of the complex in the di-
merization mode of inhibition can result in larger deviations
throughout simulation period (Fig. 5 B). While the p-S8
peptide can experience equilibrium fluctuations in the range
of 1.5 A˚ the monomer conformations can undergo larger
fluctuations reaching 2.5–3.0 A˚ range (Fig. 5, A and B). To
monitor the effect of the peptide binding on dynamics of the
HIV-1 PR monomer residues, the root mean-square fluctua-
tion (RMSF) values were also calculated, providing an esti-
mate of the average residue fluctuations taken over simulation
time (Fig. 5,C andD). In agreement with the existing body of
structural and computational data, the termini, and the flap
regions of the HIV-1 PRmonomers retain a significant degree
of flexibility in the course of simulations (Fig. 5 C). Fur-
thermore, according to our results, the HIV-1 PR monomer
termini tend to display considerably larger thermal fluctua-
tions than the conserved protease segments 24–34 and 83–93
of the folding core (Fig. 5C). This result is also consistentwith
the NMR structures of the HIV-1 PRmonomers, suggesting a
degree of disorder in the termini residues (37–40). However,
the amplitude of the termini motions tends to decrease rather
markedly after 7–8 ns of the simulation period, due to the
progressive stabilization of the interactions between the in-
hibitor and the antiparallel region of the HIV-1 PR monomer
(Fig. 5, A and B). On average, MD simulations of the peptide
binding resulted in a more rigid form of the HIV-1 PR mono-
mer in the folding mode of inhibition, whereas the dimer-
izationmode produced increased fluctuations of themonomer
residues (Fig. 5C). Conversely, the thermal fluctuations of the
p-S8 peptide residues are rather moderate in the dimerization
mode of inhibition (Fig. 5 D). These results indicate that by
stabilizing the secondary structure of the monomer termini
and mimicking a considerable portion of the dimer interface,
the folded p-S8 peptide may interfere with the dimerization of
HIV-1 PR and therefore function as a disassociation inhibitor.
These conclusions corroborate with the previous simulations
of the HIV-PR monomer in water, which have demonstrated
that the termini residues become assembled into a stable
b-sheet on a longer timescale and become considerably less
flexible (43). Consequently, a mechanism of structural mim-
icry and targeting hot spot residuesmay facilitate the inhibitor
intervention with the assembly of the folding nucleus and
HIV-1 PR dimerization.
According to many reported simulations (29,30), the
opening process of the entire flap region may be triggered by
curling of the flap tips. The ability of certain mutants to alter
the equilibrium between the open and closed conformations,
or to favor a semiopen form may lead to the drug resistant
forms of the enzyme. In particular, 70-ns MS simulations in
explicit solvent (30), which were performed on a multiple
drug-resistant mutant and a wild-type HIV-1 PR, have con-
firmed that semiopen and open enzyme forms are the two
stable forms found in the course of simulations. In our study,
we have evaluated the extent of flap motions in simulations
FIGURE 4 A closeup of the dominant binding interface determined for
the rigidly docked peptide NIIGRNLLTQI (shown in grayscale ribbons) in
the complex with the HIV-1 PR monomer (A) and a closeup of the binding
interface determined for the flexibly docked peptide (shown in grayscale
ribbons)in the complex with the HIV-1 PR monomer (B). The predicted
peptide structures reveal structural mimicry with the fireman’s-grip hydro-
gen-bond network of the active dimer, which is depicted by the superpo-
sition with the segment 24–27 of the bound HIV-1 monomer.
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by measuring the distance between residue Ile-50 (Ca) lo-
cated at the tip of the flap and the Cb of the catalytic residue
Asp-25 (Fig. 6, A and B). According to a previous definition
proposed in Perryman et al. (17) and obtained from a crystal
structure of a semiopen form of the HIV-1 PR, an I50 (Ca)-
D25(Cb) distance .15.8 A˚ would correspond to a ensemble
of semiopen conformations. A comparison of the respective
distances obtained from simulations with the folding inhibi-
tion mode (Fig. 6 A) and dimerization mode of binding (Fig.
6 B) suggests a similar dynamic behavior of the HIV-1 PR
monomer flap in these inhibitor complexes. Conformational
transitions between different flap conformations of the HIV-1
PR monomer have been monitored by measuring time evo-
lution of the distances between Ile-50 (Ca) and the Cb of the
catalytic residue Asp-25 (Fig. 6) and have revealed equilib-
rium fluctuations between semiopen and open forms. Fur-
thermore, blocking the binding interface and intervening with
the consolidation of the HIV-1 PR folding core may lead to
an additional stabilization of a semiopen flap conformation.
The respective distances at the end of the simulation are in the
range from 16 A˚ to 18 A˚ (Fig. 6, A and B), which is very
similar to the distances observed in a previous 22-ns simu-
lation of the V82F/I84V double mutant (17). The dynamics
of the HIV-1 PR monomer observed in our simulations also
closely resembles the conformational fluctuations observed
for the HIV-1 PRmonomers in 70-ns simulations of the wild-
type HIV-1 PR, which predominantly sample a semiopen
form of the enzyme and less frequently an open form, with
average flap-tip to catalytic residue distances at 18 A˚ for the
monomer A and 21 A˚ for the monomer B (30). Indeed, the
results of our 10-ns simulations have shown a similar consis-
tent emergence of the medium-range distances (15–22 A˚) and
a semiopen monomer ensemble in simulations with rare ex-
cursions into long-range distances (22–25 A˚), corresponding
to an open form. In addition, we have also estimated thermal
fluctuations of the folding core 24–34 and 83–93 segments
by monitoring time evolution of the distance between centers
of mass of these segments (Fig. 6, C and D). A greater flex-
ibility of the HIV-1 PR monomer folding core during simu-
lations of the folding inhibition mode (Fig. 6 C) may be
caused by the peptide interactions with the segment 24–34 of
the monomer, partly interfering with the optimal packing of
the folding core. The superposition of the protease monomer
conformations corresponding to the MD snapshots after ev-
FIGURE 5 (A) The RMSD values for Ca atoms along the 10-ns trajectory corresponding to the folding inhibition mode. Time evolution of the peptide is
shown in blue; time evolution of the HIV-1 PR monomer is shown in red. (B) The RMSD values for Ca atoms along the 10-ns trajectory corresponding to the
dimerization inhibition mode. Time evolution of the peptide is shown in blue; time evolution of the HIV-1 PR monomer is shown in red. (C) The RMSF values
of the HIV-1 PR monomer residues from 10-ns trajectories corresponding respectively to the folding inhibition mode (shown in blue) and dimerization mode
(shown in red). (D) The RMSF values of the peptide residues (using numbering of the 83–93 protease monomer segment) from 10-ns trajectories
corresponding respectively to the folding inhibition mode (shown in blue) and dimerization mode (shown in red).
HIV-1 Protease Folding Inhibition 557
Biophysical Journal 95(2) 550–562
ery 1 ns in the folding mode (Fig. 7 A) and dimerization mode
of binding (Fig. 7 C) illustrates the extent of flexibility in the
monomer flap during simulations. In agreement with the
NMR studies of the protease monomer, the average structures
of the peptide-monomer complex in the folding inhibition
mode (Fig. 7 B) and dimerization binding mode (Fig. 7 D)
do not produce noticeably wider flap fluctuations compared
to that of the dimer. Overall, the results ofMD simulations have
confirmed thermodynamic stability of the inhibitor complexes
with the HIV-1 PR monomers, which may have a functional
role in inhibiting HIV-1 PR folding and dimerization.
The experimental data have indicated that the active pep-
tide analogs can also inhibit the protease folding and forma-
tion of the active dimer (48–52). These peptide variants have
demonstrated a similar activity profile to the original p-S8
inhibitor, with only a marginal twofold decrease in the bind-
ing affinity. We have performed binding free energy calcu-
lations of the p-S8 peptide and the active inhibitor analogs
using MD trajectories of the p-S8 complexes with the HIV-1
PR monomers in both the folding and dimerization binding
modes. Furthermore, to compare the quality and consistency
of the energetic predictions, binding affinity evaluations have
been carried out using different MM/GBSA protocols, which
include analysis of the separate trajectories of the complex,
protein, and the inhibitor (a separate-trajectory approach) and
analysis of the trajectory of the complex (a single-trajectory
approach) (Fig. 8). In agreement with the experiment, the
results of MM/GBSA calculations have consistently revealed
that truncation of the hydrophobic Ile-93 residue does not
cause a considerable change in binding affinity, as this residue
is only peripherally involved in the interaction network at the
binding interface. A structurally predicted loss of a single
hydrogen bond in theN88Dpeptidemutant results in a greater
decrease of activity. Importantly, MD simulations of the p-S8
complex (a single trajectory approach) and an isolated p-S8
peptide (a separate trajectory approach) converge to a similar
stable, a-helix-containing structure of the inhibitor. These
data also agree with the earlier simulations of the p-S8 peptide
in explicit solvent (52), which have shown that a stable, folded
conformation of the p-S8 peptide in solution is similar to the
p-S8 bound conformation in the complex with the pS2 pep-
tide. Consequently, the binding free energy analysis derived
from single-trajectory (Fig. 8 A) and separate-trajectory (Fig.
8 B) protocols is rather similar, as the effect of structural ad-
aptation for the p-S8 peptide during binding is quitemoderate.
Interestingly, the binding free energies computed using a
single-trajectory MM/GBSA protocol underestimate some-
what the absolute binding affinities (Fig. 8 A), whereas the
binding free energies obtained from separate trajectories tend
to slightly overestimate the binding affinities of the peptides
FIGURE 6 Time evolution of the distance between Ile-50 (Ca) and the Cb of the Asp-25 in the course of 10-ns MD simulations corresponding to the folding
inhibition mode (A) and dimerization inhibition mode (B). Time evolution of the distance between centers of mass of the protease monomer segments 24–34
and 83–93. The data gathered from 10-ns MD simulations corresponding to the folding inhibition mode (C) and dimerization inhibition mode (D).
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(Fig. 8 A). Overall, the computed binding affinities are in
agreement with the experimental values and provide an ad-
ditional support to the proposed molecular basis of the inhi-
bition mechanism. While we have been able to reproduce not
only the overall trend in binding affinities, but also changes in
the binding free energy values, it is worth stressing that the
exact values of small binding free energies differences, which
are on the scale of thermal fluctuations, should be taken with
some caution as the results can be affected by numerous
factors, including the force field and the length of MD sim-
ulations. Nevertheless, a comparative analysis of the binding
free energies using both a single-trajectory and a separate-
trajectory protocols provides a rather convincing evidence to
1. The consistency in predicting the correct trend of the
binding affinity reduction in the active peptide analogs.
2. The effect of small deleterious changes in activity caused
by minor chemical modifications in the inhibitor.
Structural mimicry in binding with the HIV-1
PR monomers
The results of our study suggest that folding and binding
coupling during molecular recognition of the peptide may be
necessary to ensure structural mimicry with the key elements
of the dimer interface. According to the proposed mecha-
nism, the folding inhibitor may target the conserved HIV-1
PR regions and thereby intervene with the HIV-1 PR folding
and dimerization. Interestingly, a network of specific inter-
actions formed by the folded p-S8 peptide with the HIV-1
PR monomers does not usually include contribution of
highly structured residues from an a-helix region. Instead,
the flexible portion of the peptide may mimic the fireman’s-
grip hydrogen-bond network and stabilize the antiparallel
b-sheet of the termini. A more rigid, a-helix region of the
folded peptide provides a considerable degree of structural
mimicry with the second monomer at the binding interface.
These results are consistent with a fly-casting mechanism of
molecular recognition, which postulates that even in the
presence of stable folded monomers, a flexible region of one
of the binding partners may be utilized to bind weakly and
speed up the reaction, followed by a folding transition to the
final complex (85–87). Furthermore, in agreement with the
principle of minimal frustration, the local interactions formed
by the folding inhibitor in complexes in complexes with the
HIV-1 PRmonomers are similar to the respective interactions
detected in simulations with an isolated 24–34 segment (52).
Despite a diversity of the binding scenarios, the prevailing
mechanism of folding inhibition may be determined by the
unfrustrated inhibitor interactions with the conserved seg-
ment 24–34 of the HIV-1 PR folding nucleus. The proposed
mechanism of targeting the assembly of the HIV-1 PR
folding nucleus with the unfrustrated inhibitor may alleviate
the emergence of drug resistant strains due a reduced prob-
ability to evolve mutants at the conserved sites.
FIGURE 7 The superposition of the 10 HIV-1 PR monomer conforma-
tions corresponding to the MD snapshots after each 1 ns during 10-ns
simulation of the folding-binding mode (A) and dimerization-binding mode
(C). The average structure of the peptide complex with the HIV-1 PR
monomer obtained from 10-ns MD trajectory in the folding mode of
inhibition (B) and dimerization mode of inhibition (D).
FIGURE 8 Binding free energy analy-
sis of the inhibitor binding using a single-
trajectory protocol within theMM/GBSA
approach (A) and a separate-trajectory
protocol within the MM/GBSA approach
(B). The experimental binding free en-
ergy values are displayed in solid bars
and the computed binding free-energy
values are displayed in shaded bars.
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Although binding affinity of the p-S8 peptide inhibitor is
rather moderate compared to highly potent active site drugs,
mechanistic details of the folding inhibition mechanism
emerged from simulations may be utilized for improving
binding potency and reducing peptidic nature of the folding
inhibitor.We are currently pursuing structure-based design of
peptido-mimetics of the p-S8 peptide by retaining the rec-
ognition component of the inhibitor, which is expected to
mimic the fireman’s-grip hydrogen-bond network or stabilize
the antiparallel b-sheet of the termini. The peptidic nature of
the inhibitor is reduced through modifications of the a-helix
region. We suggest that in silico screening of the peptide
analogs for elements of structural mimicry with the HIV-1 PR
dimer interface may assist experimental techniques to probe
alternative inhibitory mechanisms, based on blocking the
assembly of the HIV-1 PR homodimer and potentially iden-
tifying new classes of dimerization HIV-1 PR inhibitors.
Exploring binding specificities of the active peptide analogs
to retroviral proteases may lead to more selective inhibitors,
since theGly-86/Arg-87/Asn-88 triad in the 83–93 segment is
rather unique to this class of proteases and constitutes a crucial
structural element involved in dimerization of the mature
HIV-1 PR. The low dimer stability of the HIV-1 PR precursor
relative to the mature protease, which is essential to allow
initial recruitment of the polyproteins, may be arguably an
apparent effect of the equilibrium between the partially folded
and the folded, enzymatically active HIV-1 PR dimer (88). In
a followup study, we are also planning to investigate whether
the inhibitory function of the folding HIV-1 PR inhibitor
could modulate equilibrium among HIV-1 PR partially un-
folded, monomeric, and dimeric states. These studies may
ultimately enable design of novel inhibitors that target the
folded precursor monomer before the maturation of the
HIV-1 protease, in contrast to inhibiting the dimerization of
the mature protease.
CONCLUSIONS
The molecular basis of the HIV-1 protease inhibition through
intervening with the protein folding and dimerization remains
largely unknown, despite rapidly increasing experimental and
theoretical efforts in this area. Considering experimental
difficulties in probing the molecular basis of folding inhibi-
tion, we have proposed a modeling approach for under-
standing the molecular basis of the HIV-1 PR folding
inhibition at atomic details. Using a combination of coarse-
grainedmolecular docking,MD simulations, and binding free
energy analysis, we have presented evidence that the folding
inhibitor may exhibit both folding and dimerization modes of
inhibition by targeting conservative elements of the HIV-1
PR. Coarse-grained molecular docking has shown that the
p-S8 peptide can fold into an a-helix-based structure of the
83–93 fragment to ensure structural mimicry with the key
elements of the dimer interface. All-atom MD simulations of
the inhibitor folding and binding with the HIV-1 PR mono-
mers provide atomic-level details of the putative binding
mechanism, which may be fulfilled via the folding mode of
inhibition (with the peptide targeting the conserved segment
24–34 of the enzyme-folding nucleus) and dimerizationmode
(with the peptide interacting with the antiparallel b-sheet of
the termini). A mechanism of structural mimicry with the
binding interface of the active dimer may reduce drug resis-
tance due to binding to the conserved regions important for
protease folding and stability. The performed microscopic
analysis reconciles the experimental and computational re-
sults and rationalizes the molecular basis of folding inhibition
for the active peptide analogs.
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